Zoetis (ZTS)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$75.81-0.63%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · ZTS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 3.3% |
| Our one-year growth estimate | diamond | -0.8% |
Growth built into the price is above our model estimate.
The price assumes 4.0 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 23 industry peers · Company calendar date is not available
ZTS — dividend update
Dated 2026-05-20
Regulation FD Disclosure. On May 20, 2026, the Company declared a dividend of $0.53 per share for the third quarter of 2026. The dividend will be paid on September 1, 2026, to all holders of record of the Company’s common stock as of the close of business on July 20, 2026. The information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Secur…
Why it matters: This acquisition could help Zoetis improve livestock products. It may change future earnings.
Supportive ifThe Neogen acquisition will finish before the end of 2026.
Worry ifThe acquisition is delayed or called off.
Why it matters: New product approvals are key for revenue growth. They help in a tough market.
Supportive ifLook for at least one new product approval from the 12 potential blockbusters.
Worry ifNo new product approvals announced in the next quarter.
Why it matters: If guidance stabilizes, it shows management is confident. This means they can adapt to market changes.
Supportive ifFull year 2026 revenue guidance stabilizes within the range of $9.120 billion to $9.320 billion.
Worry ifRevenue guidance may go down to below $9.120 billion.
Why it matters: If sector revenue growth slows, it may impact Zoetis' performance. This could change investor outlook.
Worry ifSector revenue growth falls below its median rate.
Less concerning ifSector revenue growth remains above its median rate.
Why it matters: A drop below this level shows a big slowdown in growth.
Worry if2026 guidance for organic revenue growth is below 2%.
Less concerning if2026 guidance for organic revenue growth stays at or above 2%.
Why it matters: EPS guidance will indicate how profit expectations are changing. This affects how investors view the company's future.
Supportive ifManagement expects higher EPS for 2026. This is above current forecasts.
Worry ifManagement lowers EPS guidance for 2026 or keeps it unchanged.
Why it matters: Trends in this segment help us understand how the company is doing overall.
Worry ifU.S. Companion Animal revenue declines more than 10% year over year.
Less concerning ifU.S. Companion Animal revenue stabilizes or grows year over year.
Why it matters: Increased competition in these segments could hurt revenue. This is critical for Zoetis' growth strategy.
Worry ifSales in skin care and parasite treatments fell by over 10% from last year.
Less concerning ifSales in skin care and parasite treatments stay the same or increase from last year.
Why it matters: Stable operating income helps keep profits. A drop may mean cost issues.
Supportive ifOperating income was above $758 million in Q2 2026.
Worry ifOperating income was below $758 million in Q2 2026.
Why it matters: The U.S. segment saw a significant decline in Q2. Continued weakness could signal deeper issues in the market.
Worry ifU.S. segment revenue declines more than 7% year over year in Q3.
Less concerning ifU.S. segment revenue stabilizes or grows year over year.
Why it matters: A confirmed dividend shows the company's commitment to returning cash to shareholders. This can boost investor trust.
Supportive ifManagement confirms the dividend of $0.53 per share will be paid as planned.
Worry ifManagement delays or cuts the dividend payment for Q3 2026.
Why it matters: Growth in the international segment helps keep revenue stable. It shows success in expanding markets.
Supportive ifInternational segment revenue grows by more than 6% compared to last year.
Worry ifInternational segment revenue growth is less than 4% compared to last year.
Why it matters: If revenue growth is below 2%, it signals ongoing challenges in the U.S. market. This would raise concerns about the company's ability to drive growth amid increased competition.
Worry ifQ2 2026 revenue growth reported below 2% year over year.
Less concerning ifQ2 2026 revenue growth reported at 2% or higher year over year.
Why it matters: The revenue growth guidance will show how management plans to boost sales. This is key for investor confidence.
Supportive ifManagement expects higher revenue growth for 2026. This is above what people thought before.
Worry ifManagement lowers revenue growth guidance for 2026 or keeps it unchanged.
Why it matters: The dividend news shows the company is doing well and cares about shareholders.
Watch forAnnouncement of a dividend increase for Q3 2026.
Also watch forAnnouncement of a dividend cut or suspension for Q3 2026.
Why it matters: New product approvals can help Zoetis make more money. This is important for staying ahead.
Supportive ifLook for at least one new product approval. It should meet a big need in animal health.
Worry ifIf there are no new product approvals by the end of 2026, it may mean delays.
Why it matters: A further downward revision would signal ongoing challenges in revenue growth. This could impact investor confidence.
Worry ifManagement cuts 2026 revenue forecast to less than $9.12 billion.
Less concerning ifRevenue guidance remains at or above $9.12 billion.
Why it matters: New product approvals help grow revenue and meet market challenges.
Supportive ifAnnouncement of at least one new product approval in a major market.
Worry ifNo new product approvals announced in Q3.
Why it matters: Changes in cost management may affect profits and how well the company runs.
Watch forManagement shares a new plan to cut costs or change SG&A expenses.
Also watch forManagement says there are no changes to current cost management plans.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$135 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $312 loss on $10,000 · 3.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,256 loss on $10,000 · 52.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.